Drugs / SCTB41
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07819188 | Sep 2026 → Sep 2028 expected | non-Hodgkin lymphoma | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07665970 | Jun 2026 → Jun 2029 expected | cancer | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07594028 | May 2026 → May 2029 expected | cancer | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06600022 | Oct 2024 → Apr 2027 expected | cancer | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07609251 | May 2026 → Oct 2028 expected | non-small cell lung carcinoma | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07662395 | May 2026 → Jan 2030 expected | — | Sinocelltech Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTB41 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07665970 ↗ |
| Route | Intravenous | “SCTB41 of different doses,IV,every 3 weeks” NCT06600022 ↗ |